Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4485 Inpatient admissions for hormone secretion management in patients with neuroendocrine neoplasms (NEN) treated with [177Lu]Lu-DOTA-Octreotate (LuTate) therapy over a 4.5 year period at a single high volume treatment centre

Introduction: LuTate therapy is an effective treatment for patients with somatostatin receptor expressing NEN. However, patients (pts) with functional tumours may develop an acute flare of symptoms during or after PRRT.

Conference:

Presenting Author: Kong G

Authors: Neeson L, Boehm E, Chiang C, Michael M, Sachithanandan N,

Keywords: PRRT, NET, high-risk, flare, outcomes, NEN, single centre,

#3952 Peptide Receptor Radionuclide Therapy (PRRT) in the management of patients with ectopic Cushing’s syndrome due to metastatic gastroenteropancreatic neuroendocrine neoplasia (GEPNEN): A single centre experience

Introduction: Metastatic GEPNEN can cause ectopic Cushing’s syndrome (ECS). ECS is highly morbid and often refractory to medical therapy. Bilateral adrenalectomy (BA) carries risk and long-term morbidity. Patients (pts) unsuitable for surgery have dismal outcomes. Peptide receptor radionuclide therapy (PRRT) is a rational option for hormone control in ECS caused by NEN with high somatostatin receptor (SSTR) expression yet detailed case series to guide its use are lacking.

Conference:

Presenting Author: Boehm E

Authors: Boehm E, Hung T, Akhurst T, Alipour R, Cardin A,

Keywords: GEPNEN, PRRT, Ectopic Cushing's Syndrome,